Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire November 10, 2025 Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full […]